Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 327 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Radiotherapy; Complications Clear all
Recruiting Phase 1Phase 2 Interventional

Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer

NCT06529809
View directory record Official record
Conditions
Locally Advanced Cervical Carcinoma
Interventions
Hypofractionated external beam radiation, Chemotherapy, Image-guided brachytherapy
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jun 10, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer

NCT00258362
View directory record Official record
Conditions
Endometrial Cancer
Interventions
carboplatin, docetaxel, radiation therapy
Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Jun 10, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

NCT01101451
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage I Cervical Cancer AJCC v6 and v7, Stage IA Cervical Cancer AJCC v6 and v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7
Interventions
Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Drug · Radiation · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
698
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 433 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Jun 10, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

NCT00981656
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, 5-fluorouracil, Mitomycin, Three-Dimensional Conformal Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
13
States / cities
Atlanta, Georgia • Baltimore, Maryland • Fall River, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 10, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional

Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies

NCT07447895
View directory record Official record
Conditions
Cervical Cancer, Radiation Therapy Complication, Pelvic Floor Disorders
Interventions
Pelvic floor physical therapy
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 10, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

NCT00853125
View directory record Official record
Conditions
Kidney Cancer
Interventions
therapeutic allogeneic lymphocytes, sunitinib malate
Biological · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Jun 10, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Low-Dose Radiation to Prevent Complications of Back Surgery

NCT00018876
View directory record Official record
Conditions
Failed Back Surgery Syndrome, Postlaminectomy Syndrome, Postdiscectomy Epidural Fibrosis
Interventions
Lumbar nerve root decompression, Preoperative low-dose external beam radiation
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Jun 10, 2026, 4:14 AM EDT
Recruiting Phase 2 Interventional

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

NCT07223541
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jun 10, 2026, 4:14 AM EDT
Recruiting No phase listed Observational

Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy

NCT07214584
View directory record Official record
Conditions
Cervical Cancer, Human Papilloma Virus (HPV)
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 10, 2026, 4:14 AM EDT
Completed Not applicable Interventional

System for High-Intensity Evaluation During Radiotherapy

NCT04277650
View directory record Official record
Conditions
Radiation Therapy Complication, Chemotherapeutic Toxicity
Interventions
Machine learning algorithm
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 10, 2026, 4:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

NCT02466971
View directory record Official record
Conditions
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
Brachytherapy, Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Radiation Therapy, Triapine
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
378
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 253 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 4:14 AM EDT
Suspended Phase 2 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

NCT03575611
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 10, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

NCT01104350
View directory record Official record
Conditions
Bladder Cancer
Interventions
external radiation therapy with gemcitabine
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 10, 2026, 4:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

NCT03474497
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
IL-2, Pembrolizumab, Radiotherapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 10, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

NCT00121420
View directory record Official record
Conditions
Neoplasm Metastasis, Brain Neoplasms
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jun 10, 2026, 4:14 AM EDT
Active, not recruiting Phase 2 Interventional

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

NCT02306954
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
High Dose IL-2, SBRT
Biological · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jun 10, 2026, 4:14 AM EDT
Terminated Not applicable Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

NCT02542202
View directory record Official record
Conditions
Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Jun 10, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

NCT00369122
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7
Interventions
Bevacizumab, Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
103
States / cities
Burbank, California • Sacramento, California • Colorado Springs, Colorado + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Jun 10, 2026, 4:14 AM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT05283330
View directory record Official record
Conditions
Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions
²¹²Pb-DOTAM-GRPR1
Drug
Lead sponsor
Orano Med LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
4
States / cities
Chicago, Illinois • Lexington, Kentucky • Glen Burnie, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 10, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

FLT PET Imaging for Cervical Cancer

NCT01075412
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
[F18]Fluorothymidine
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Jun 10, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional

Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries

NCT00134628
View directory record Official record
Conditions
Radiation Injuries
Interventions
Hyperbaric Oxygen Therapy, Sham treatment
Procedure
Lead sponsor
National Baromedical Services
Other
Eligibility
Not listed
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Jun 10, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

NCT05975593
View directory record Official record
Conditions
Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer, Cervical Cancer, Pancreas Cancer, Pancreatic Cancer, Cancer of the Cervix, Cancer of the Pancreas
Interventions
Tumor collection via biopsy, Blood collection, Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)
Other · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jun 10, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy

NCT00077064
View directory record Official record
Conditions
Lung Cancer, Pulmonary Complications, Radiation Fibrosis
Interventions
captopril
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
87
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Jun 10, 2026, 4:14 AM EDT
Withdrawn Phase 2 Interventional

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

NCT03150836
View directory record Official record
Conditions
Bladder Cancer
Interventions
Durvalumab, Tremelimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Terence Friedlander, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Jun 10, 2026, 4:14 AM EDT